Since Tax K63-linked polyubiquitination is required for constitutive NF-κB activation and subsequent immortalization and transformation of CD4+ T cells, UBE4B may represent a novel therapeutic target for Tax+ ATLL tumors (~40% of ATLL tumors express Tax sporadically). The gene discussed is NFKB1; the disease is adult T-cell leukemia/lymphoma.